Safety and Dosing Study of a Cholecystokinin Receptor Antagonist in Non‐alcoholic Steatohepatitis. Issue 6 (27th September 2022)

• Record Type: Journal Article
• Authors: Rabiee, Atoosa; Gay, Martha D.; Shivapurkar, Narayan; Cao, Hong; Nadella, Sandeep; Smith, Coleman I.; Lewis, James H.; Bansal, Sunil; Cheema, Amrita; Kwagyan, John; Smith, Jill P.
• Is Part Of: Clinical pharmacology & therapeutics. Volume 112:Issue 6(2022)
• Page Start: 1271
• Page End: 1279
• Publication Date: 2022-09-27
• Subjects: Pharmacology -- Periodicals; Therapeutics -- Periodicals; 615.5
• DOI: 10.1002/cpt.2745
• Languages: English
• ISSNs: 0009-9236

Abstract

Abstract : High saturated fat diets have been shown to raise blood levels of cholecystokinin (CCK) and induce nonalcoholic steatohepatitis (NASH). CCK receptors are expressed on stellate cells and are responsible for hepatic fibrosis when activated. The purpose of this study was to test the safety and dose of a CCK receptor antagonist, proglumide, in human participants with NASH. An open‐label single ascending dose study was conducted in 18 participants with clinical NASH based upon steatosis by liver ultrasound, elevated hepatic transaminases, and a component of the metabolic syndrome. Three separate cohorts ( N = 6 each) were treated with oral proglumide for 12 weeks in a sequential ascending fashion with 800 (Cohort 1), 1, 200 (Cohort 2), and 1, 600 (Cohort 3) mg/day, respectively. Blood hematology, chemistries, proglumide levels, a biomarker panel for fibrosis, and symptom surveys were determined at baseline and every 4 weeks. Abdominal ultrasounds and transient elastography utilizing FibroScan were obtained at baseline and at Week 12. Proglumide was well tolerated at all doses without any serious adverse events. There was no change in body weight from baseline to Week 12. For Cohorts 1, 2, and 3, the median percent change in alanine aminotransferase was 8.42, −5.05, and −22.23 and median percent change in fibrosis score by FibroScan was 8.13, −5.44, and −28.87 (kPa), respectively. Hepatic steatosis as measured by controlled attenuation parameter score significantly decreased with proglumide, ( P < 0.05). Blood microRNA biomarkers and serum 4‐hydroxyproline were consistent with decreased fibrosis at Week 12 compared with baseline. These findings suggest proglumide exhibits anti‐inflammatory and anti‐fibrotic properties and this compound is well tolerated in participants with NASH.